Congress-AHA
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2026

Congress Details

calanderMarch 28-30, 2026

location New Orleans, LA, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

28 March, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
11:24 – 11:31 am CST
location icon Location
Moderated Poster Theater 12, Posters, Hall E
icon Title
Post hoc analysis of diastolic dysfunction in the HELIOS-B study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
mic Presenter

Jose Gonzalez-Costello

Bellvitge University Hospital, Barcelona, Spain

Audio recording at embargo lift
Coming soon
icon Presentation Type
Moderated poster
time icon Time
9:30–10:30 am CST
location icon Location
Poster, Posters, Hall E
icon Title
Polypharmacy and potential for drug-drug interactions among patients with ATTR-CM initiating treatment with tafamidis
mic Presenter

Robert DiDomenico 

Retzky College of Pharmacy, IL, USA

Audio recording at embargo lift

29 March, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
4:18 pm – 4:25 pm CST
location icon Location
Moderated Poster Theater 11, Posters, Hall E
icon Title
Impact of vutrisiran on the components of quality of life in transthyretin cardiomyopathy (ATTR-CM)
mic Presenter

Yasuhiro Hamatani

Brigham and Women's Hospital, MA, USA

Audio recording at embargo lift

30 March, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
11:24 am – 11:31 am CST
location icon Location
Moderated Poster Theater 09, Posters, Hall E
icon Title
Vutrisiran reduces the risk of developing advanced disease and demonstrates benefit in patients who do develop advanced disease in ATTR-CM: analysis from the HELIOS-B study
mic Presenter

Ronald Witteles 

Stanford University, CA, USA

Audio recording at embargo lift
Coming soon
icon Presentation Type
Moderated poster
time icon Time
11:12 am – 11:19 am CST
location icon Location
Moderated Poster Theater 09, Posters, Hall E
icon Title
Real world adherence and persistence with vutrisiran, an RNAi therapeutic for the treatment of transthyretin amyloidosis
mic Presenter

Michael Heffernan 

McMaster University, Ontario, Canada

Audio recording at embargo lift

Related Materials

Congress-ISPOR-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

November 9-12, 2025 UK

View Details
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2025

November 7-10, 2025 USA

View Details

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

September 2025

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

September 2025

Congress-HFSA-Mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

September 26-29, 2025 USA

View Details
Congress-EU-ATTR-Mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

September 25-26, 2025 ITALY

View Details